FOXO TECHNOLOGIES INC. (FOXO): Entry into a Material Definitive Agreement

FOXO TECHNOLOGIES INC. (FOXO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 FOXO TECHNOLOGIES INC. ANNOUNCES AGREEMENTS TO ACQUIRE PREFERRED STOCK CARRYING MAJORITY VOTING POWER IN LUDWIG ENTERPRISES, INC. WEST PALM BEACH, FL, October 29, 2026 (GLOBE NEWSWIRE) — FOXO Technologies Inc . (OTC: FOXO) (“FOXO” or the “Company”) today announced th

Event · M&A · announced
Role
acquirer
Counterparty
Ludwig Enterprises, Inc.
Seller
Thomas E. Terwilliger, individually, whose revocable trust is one of the selling preferred stockholders
Consideration
stock

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 29, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$FOXO
Neutral
medium confidence
Mentioned
$FOXO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FOXONeutralMed
01

Why it matters

The announced agreements could provide FOXO with new mRNA diagnostic technology but hinge on regulatory and financing milestones.

02

Market read

Primary disclosure of a pending acquisition; modest impact expected pending Nasdaq listing and financing.

03

What to watch

Financing terms and the valuation of Ludwig's preferred stock are undisclosed, adding risk.

Relevance 6/10Novelty 7/10Timing: on the filing date, Oct 29 2026

Background

FOXO Technologies Inc. is an OTC‑listed health‑care company with subsidiaries in hospitals, behavioral health, biospecimen sourcing, and biotech.

Company-level read

Ticker impact

$FOXONeutralMedium confidence
Context

FOXO filed an 8‑K announcing stock purchase agreements to acquire preferred shares of Ludwig Enterprises, a material definitive agreement.

Expected impact

possible upward pressure if Nasdaq listing and financing succeed, otherwise limited impact

Evidence & confidence

The deal is pending and contingent on financing and Nasdaq approval, creating uncertainty around immediate price effect.

Market effects

May signal increased M&A activity in the niche mRNA diagnostic sector.

Limited to U.S. OTC market; no broader regional effect.

Low global relevance beyond niche biotech investors.

Counterpoint

If Nasdaq listing fails, the acquisition could collapse, leading to a sell‑off in FOXO.

Key entities

  • FOXO Technologies Inc.

    OTC‑listed health‑care firm filing the 8‑K.

  • Ludwig Enterprises, Inc.

    Nevada biotech developing mRNA biomarker platform.

Related articles

$MTBMed

M&T Bank Just Raised Its Dividend 20% as Earnings Support a Bigger Payout

M&T Bank (MTB) raised its quarterly dividend 20% to $1.80 per share, payable December 31, 2026. The bank's third-quarter earnings per share (EPS) were $5.04, with a forward yield of about 3.3%. M&T's CET1 ratio is 10.16%, and it has repurchased $1.25 billion of stock in Q1, $465 million in Q2, and $323 million in Q3. The bank's dividend payout ratio is approximately 36% of its quarterly profit.

$GFFMed

Griffon Q4 Earnings Call Highlights

Griffon (NYSE:GFF) completed transactions reducing debt by $364 million, refinanced bonds, and secured a $500 million credit agreement. It increased share repurchases by $400 million and raised its quarterly dividend by 14%. The company gained garage door market share and returned $177 million to shareholders. Net debt stood at $947 million as of Sept. 30.